Gong Hongtao, Mu Liying, Zhang Tong, Xu Xiuying, Du Fenghe
Department of Cardiology, Beijing Tiantan Hospital, Capital University of Medical Science, Beijing, People's Republic of China.
J Genet. 2019 Mar;98.
The aim of this study was to determine whether the polymorphism of aldosterone synthase () -344C/T and angiotensin-converting enzyme () insertion/deletion (I/D) were associated with the response of blood pressure (BP) to telmisartan treatment. After a two-week single-blind placebo run-in period, 148 patients with mild-to-moderate primary hypertension received monotherapy of telmisartan with 80 mg/day and then were followed up for eight weeks. Polymorphisms of -344C/T and I/D gene were determined through polymerase chain reaction-restriction fragment polymorphism analysis. The relationship between these polymorphisms and changes in BP was monitored and evaluated after eight weeks of treatment. With respect tothe polymorphism of -344C/T, the reduction in diastolic BP was significantly greater in patients carrying the C allele (CC+CT) compared with those carrying the TT genotype. There was no significant differences between I/D polymorphism and BP reduction after treatment. We concluded that the aldosterone synthase -344C/T polymorphism was related to the antihypertensive treatment with telmisartan in hypertensive patients.
本研究旨在确定醛固酮合酶()-344C/T多态性和血管紧张素转换酶()插入/缺失(I/D)是否与替米沙坦治疗的血压(BP)反应相关。在为期两周的单盲安慰剂导入期后,148例轻至中度原发性高血压患者接受每日80mg替米沙坦单药治疗,随后随访8周。通过聚合酶链反应-限制性片段长度多态性分析确定-344C/T和I/D基因的多态性。治疗8周后监测并评估这些多态性与血压变化之间的关系。关于-344C/T多态性,携带C等位基因(CC+CT)的患者舒张压降低幅度明显大于携带TT基因型的患者。治疗后I/D多态性与血压降低之间无显著差异。我们得出结论,醛固酮合酶-344C/T多态性与高血压患者替米沙坦降压治疗有关。